From: Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis
Parameter | Respondersa | Non-responders | ||
---|---|---|---|---|
Subset 1b (n = 6) | Subset 2 (n = 10) | Subset 1 (n = 7) | Subset 2 (n = 10) | |
Age (years) | 54.1 ± 13.8c | 55.2 ± 9.2 | 56.1 ± 11.7 | 58.9 ± 11.6 |
Sex (men/women) | 1/5 | 2/8 | 1/6 | 4/6 |
RA duration (years) | 11.7 ± 8.0 | 11.1 ± 7.3 | 12 ± 10.2 | 10.5 ± 5.3 |
Methotrexate (mg/week)d | 12.5 ± 5.5 | 13 ± 2.8 | 15.4 ± 2.7e | 11.5 ± 3.2 |
Prednisone (mg/day) | 12.1 ± 5.6 | 8.5 ± 4.2 | 10.3 ± 8.7 | 8.2 ± 5.4 |
Patients with NSAIDs | 3 | 6 | 5 | 4 |
Patients with rheumatoid factor | 4 | 8 | 5 | 6 |
Patients with anti-CCP absg | 3 | 8 | 5 | 8 |